Back to top
more

GENEDX HOLDINGS (WGS)

(Delayed Data from NSDQ)

$26.19 USD

26.19
288,656

-1.06 (-3.89%)

Updated Jun 26, 2024 04:00 PM ET

After-Market: $26.14 -0.05 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for WGS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for GeneDx Holdings Corp falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 130 137 401 1 0
Receivables 33 43 27 0 0
Notes Receivable 0 0 0 0 0
Inventories 9 14 33 0 0
Other Current Assets 11 18 23 0 0
Total Current Assets 182 213 484 1 0
Net Property & Equipment 32 52 63 0 0
Investments & Advances 0 0 0 443 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 173 187 0 0 0
Deposits & Other Assets 4 7 8 0 0
Total Assets 419 491 554 444 0
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 37 46 45 0 0
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 3 0 0
Accrued Expenses 0 39 20 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 18 53 33 0 0
Total Current Liabilities 59 144 101 0 0
Mortgages 0 0 0 0 0
Deferred Taxes/Income 2 3 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 53 6 11 0 0
Non-Current Capital Leases 0 0 18 0 0
Other Non-Current Liabilities 15 24 35 439 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 191 237 166 439 0
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,528 1,378 964 5 0
Retained Earnings -1,300 -1,124 -575 0 0
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 228 254 388 5 0
Total Liabilities & Shareholder's Equity 419 491 554 444 0
Total Common Equity 228 254 388 5 0
Shares Outstanding 25.90 11.70 7.30 1.60 NA
Book Value Per Share 8.80 21.68 53.16 3.13 0.00

Fiscal Year End for GeneDx Holdings Corp falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 113 130 114 157 214
Receivables 29 33 32 34 34
Notes Receivable 0 0 0 0 0
Inventories 12 9 9 12 12
Other Current Assets 10 11 16 11 12
Total Current Assets 163 182 172 213 272
Net Property & Equipment 31 32 36 43 50
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 169 173 176 180 183
Deposits & Other Assets 4 4 6 6 7
Total Assets 395 419 417 476 545
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 32 37 39 55 70
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 14 18 26 24 44
Total Current Liabilities 51 59 68 84 119
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1 2 2 2 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 52 53 6 6 6
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 21 23 24 25
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 187 191 163 180 217
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,527 1,528 1,529 1,528 1,514
Retained Earnings -1,320 -1,300 -1,274 -1,232 -1,185
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 207 228 254 296 328
Total Liabilities & Shareholder's Equity 395 419 417 476 545
Total Common Equity 207 228 254 296 328
Shares Outstanding 26.10 25.90 25.80 25.70 24.10
Book Value Per Share 7.94 8.80 9.86 11.52 13.63